Biogen will pay City Therapeutics $46m, which includes $16m upfront and $30m investment for a convertible note.

China continues to be a source of innovation as Pfizer strikes biggest pact yet; HHS provides more info on Trump’s Most ...

Biogen and Eisai have resurrected hopes that amyloid-targeting drugs could have a benefit in Alzheimer's disease with a claim that their new drug lecanemab showed a "highly statistically ...

Analysts at BMO Capital Markets said in a weekend note that a non-invasive blood test could help boost uptake of Alzheimer’s ...

Lecanemab was approved in the U.S. in 2023 as the world's first drug to slow the cognitive decline associated with Alzheimer's. The treatment also has received approval in Japan, China, Europe and ...

The Food and Drug Administration cleared a new kind of test for Alzheimer’s disease designed to be more accessible and less ...

The test potentially makes it easier to find and treat patients with the memory-robbing disease. Read more at ...

The Food and Drug Administration has cleared Fujirebio Diagnostics’ blood test to diagnose Alzheimer’s disease, the regulator ...

U.S. regulators have approved the first blood test to help diagnose Alzheimer’s disease, potentially making it easier to find ...

The Lumipulse Alzheimer's blood test is the first of a new generation of tests that may replace brain scans and spinal taps ...